Sudden interest has surrounded Revolution Medicines, a biotech focused on RAS-addicted cancers, as reports surfaced that Merck and possibly AbbVie have considered acquiring the company. According to The Wall Street Journal, Merck recently dropped out of acquisition talks after both parties failed to agree on a final price. Earlier reporting from The Financial Times indicated that Merck was considering an offer in the range of $28 billion to $32 billion.
Truist Securities commented on Revolution’s decision not to accept the deal: “In our view, given a potential transaction in the $30 billion range was reportedly being discussed is a nice validation of RVMD’s value and could be a good watermark for other potential suitors to consider,” Truist stated in a note to investors. “We continue to believe that RVMD is well funded and doesn’t need to do a deal.”
Following news that Merck withdrew from discussions, Revolution’s shares dropped by 16% on Monday morning, trading at $97.91.
Despite this development, speculation about future buyouts persists. William Blair noted last week: “some [investors are] even placing side bets on how many weeks it will be until Revolution Medicines could be acquired.”
At the J.P. Morgan Healthcare Conference earlier this month, Revolution CEO Mark Goldsmith declined to comment directly on acquisition rumors but said: “But with regard to what are we building, it’s not our goal to build something big,” Goldsmith said. “It’s our goal to build something that’s impactful.”
Founded in 2015 with $45 million in funding, Revolution initially set out to synthesize natural products before shifting focus toward RAS(ON) inhibitors. Its lead asset daraxonrasib has shown promise in clinical trials; as of September 2025, it demonstrated a 29% confirmed objective response rate (ORR) as a second-line treatment for pancreatic cancer patients with RAS mutations and achieved a 47% ORR as first-line therapy.
The U.S. Food and Drug Administration recognized these results by granting daraxonrasib a Commissioner’s National Priority Voucher in October 2025—an action expected to shorten its review time significantly.
Revolution also has additional candidates in development. Elironrasib targets solid tumors with RAS(ON) G12C mutations and is currently undergoing early-stage trials for lung cancer. Zoldonrasib is positioned within the competitive KRAS G12D space; according to Goldsmith, tolerability data compares favorably with placebo and patient numbers exceed those enrolled for similar investigational agents.
However, overlap between Revolution's elironrasib and Merck's own KRAS G12C candidate MK-1084 may have complicated merger discussions due to possible regulatory concerns from the Federal Trade Commission regarding redundancy within Merck's pipeline.
“MRK might have had issues paying for an asset that was going to be redundant,” Truist said.
Merck CEO Rob Davis remarked at J.P. Morgan: “We are not limited from a balance sheet.” He added that Merck could spend “multi tens of billions of dollars,” reflecting strong financial backing from its oncology portfolio led by Keytruda.
Truist analysts remain open-minded about future developments: “While a deal with MRK appears to be a no-go today, we won’t rule them out from having interest in the future,” they wrote.
Should another buyer emerge for Revolution Medicines at this scale, BMO Capital Markets suggested it would signal renewed interest in large-scale mergers and acquisitions within biopharma—a shift away from recent trends favoring smaller deals under $20 billion.
Other companies such as Eli Lilly, Pfizer, Roche (all of which possess similar pan-KRAS inhibitors), Bristol Myers Squibb (which owns Krazati but lacks further KRAS assets), Novartis (with non-overlapping small molecules), and AbbVie have all been mentioned as potential acquirers or interested parties by Truist analysts.
AbbVie management has denied pursuing such an acquisition so far; however, some analysts have not excluded them entirely from consideration.
